Home

Chau Quang Khuong

CIK 1609405 · last filed 2023-06-23

Chau Quang Khuong is a corporate insider who has filed 70 SEC Form 4 insider transactions across 8 companies since 2014. Across all open-market trades the lifetime net is −$141.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.16M

Companies

8

Total Filings

70

Lifetime Open-Market Net

-$141.53M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NXTC Director 196,751 $5.42 $1.07M $5.25M 6 2023-06-23
Damora Therapeutics, Inc. (GLTO) Delisted Director 41,272 $28.69 $1.18M $11.00M 5 2023-06-15
Fusion Pharmaceuticals Inc. (FUSN) Delisted Director 234,193 $21.55 $5.05M $15.27M 6 2023-06-14
SYNLOGIC, INC. (SYBX) Delisted Director 246,444 $0.69 $170.0K $0 7 2021-04-22
INSP Director 1,875 $51.97 $97.4K -$168.53M 21 2020-10-13
Whitehawk Therapeutics, Inc. (ARPO) Delisted Director 346,263 $33.00 $11.43M $2.99M 2 2019-06-19
PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Director 89,928 $13.60 $1.22M $1.38M 12 2017-10-27
OTONOMY, INC. (OTIC) Delisted Director 1,850,684 $0.08 $142.5K -$8.89M 6 2016-06-21

Recent Filings

70 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-12-14 — Notice (144) −22,093 -$121.5K EDGAR
2023-12-08 — Notice (144) −22,093 -$127.0K EDGAR
2023-06-23 NXTC Grant (A) — $0 EDGAR
2023-06-15 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
2023-06-14 Fusion Pharmaceuticals Inc. (FUSN) Delisted Grant (A) — $0 EDGAR
2022-11-14 Fusion Pharmaceuticals Inc. (FUSN) Delisted Grant (A) +42,093 $100.2K EDGAR
2022-06-24 NXTC Grant (A) — $0 EDGAR
2022-06-22 Fusion Pharmaceuticals Inc. (FUSN) Delisted Grant (A) — $0 EDGAR
2022-06-15 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
2021-11-19 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 70
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.